MARKET

ARVN

ARVN

Arvinas
NASDAQ
12.79
+0.24
+1.91%
After Hours: 12.90 +0.11 +0.86% 19:48 12/05 EST
OPEN
12.60
PREV CLOSE
12.55
HIGH
12.91
LOW
12.57
VOLUME
950.92K
TURNOVER
--
52 WEEK HIGH
26.94
52 WEEK LOW
5.90
MARKET CAP
821.43M
P/E (TTM)
-15.8902
1D
5D
1M
3M
1Y
5Y
1D
Arvinas Holding Company (ARVN) Receives a Buy from Piper Sandler
TipRanks · 18h ago
Weekly Report: what happened at ARVN last week (1124-1128)?
Weekly Report · 4d ago
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
Seeking Alpha · 11/27 12:20
Arvinas Executives to Present at Piper Sandler Annual Healthcare Conference
Reuters · 11/26 12:00
Arvinas And Pfizer's Vepdegestrant Featured In Multiple Abstracts Accepted For SABCS 2025, Highlighting Novel PROTAC ER Degrader In ER+/HER2- Breast Cancer
Benzinga · 11/24 12:09
Arvinas Highlights Vepdegestrant Breast Cancer Data at 2025 SABCS
Reuters · 11/24 12:00
ARVINAS ANNOUNCES DATA PRESENTATIONS FROM THE VEPDEGESTRANT (ARV-471) CLINICAL DEVELOPMENT PROGRAM AT THE 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)
Reuters · 11/24 12:00
Weekly Report: what happened at ARVN last week (1117-1121)?
Weekly Report · 11/24 09:20
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.